Ipca Labs plant blasted by FDA for a 'cascade of failure'

FDA Building 2
The FDA has issued a 10-page Form 483 for an Ipca Laboratories plant in India that has previously be criticized for manufacturing failures. (FDA)

An Ipca Laboratories plant savaged in an FDA warning letter three years ago continues to fail manufacturing standards that would assure its drugs are safe and effective. The FDA says that is “demonstrated by a cascade of failure” in the quality unit of the Indian plant. 

These failures at the finished products plant in Silvassa are detailed (PDF) in an FDA Form 483 that followed an inspection last month. There are only three observations, but the list of issues stretches to 10 pages. 

RELATED: FDA warning to Ipca Labs shines light on rampant data falsification

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

It says the plant quality unit allows batches to be released for use without properly reviewing out-of-specification and out-of-trend investigations, routine quality control (QC) testing worksheets or electronic data to ensure they meet standards.  

It says some corrective actions on change of controls were open for two years while analysts have not properly followed dissolution testing procedures for more than a decade. 

RELATED: India's troubled Ipca buys U.S. API maker 

The FDA has been down this road with Ipca before. The Silvassa plant was one of three that was slammed in a warning letter in 2016 for serious data manipulation and falsification. The FDA said the problem was rampant at that company, enforced by senior managers in the QC unit to keep product supply flowing.

Ipca has told the FDA in the past that it will get the problems under control, and the problems have not kept it from expanding in the U.S. Last year, it paid nearly $10 million for Pisgah Labs, an API maker based in Pisgah Forest, North Carolina.

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.